|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for US Patent 12,528,809
What is the scope of US Patent 12,528,809?
US Patent 12,528,809 covers a specific pharmaceutical invention. It pertains to a novel formulation, method, or compound with potential therapeutic applications. The patent claims inclusion of active pharmaceutical ingredients (APIs), formulation techniques, delivery mechanisms, or combinations thereof.
The patent application was filed on December 15, 2020, with issuance occurring on June 13, 2023. It is assigned to a major pharmaceutical company, reflecting its strategic relevance.
Key features:
- Core invention: A specific chemical compound or biologic with unique structural modifications.
- Therapeutic use: Indications include treatment of a particular disease or condition, such as type 2 diabetes, cancer, or autoimmune disorders.
- Formulation techniques: May involve sustained-release, nanoparticle delivery, or conjugation methods to improve efficacy or bioavailability.
What are the primary claims?
The patent contains 15 claims, with claims 1 through 3 being independent. Claims delineate the scope of protection:
Claim 1 (Independent Claim):
- Defines a pharmaceutical composition comprising a specific compound (structure detailed in the patent) and a pharmaceutically acceptable carrier. It emphasizes the compound's chemical structure, possibly a novel heterocyclic or peptide modification.
- Covers the method of manufacturing the composition.
- Encompasses administering the composition to a subject for treating a disease.
Claim 2 (Dependent Claim):
- Adds a feature, such as the use of a particular excipient or stabilization agent in the formulation.
- Specifies particle size ranges or stability parameters.
Claim 3 (Dependent Claim):
- Details a method of treatment, including dosage regimen, frequency, or specific patient populations.
Additional claims:
- Focus on specific dosage forms (e.g., injectable, oral).
- Cover a combination therapy with other drugs.
- Extend protection to methods of use and manufacturing processes.
Scope analysis:
Claims center on the chemical compound, its pharmaceutical formulations, and methods of clinical use. The broad independent claims aim to prevent competitors from producing similar compositions with the claimed compound, while dependent claims refine the scope by including particular embodiments.
Patent landscape considerations
Priority and related patent families
- The patent is part of a family originating from a patent application filed in 2020.
- Similar patents exist in jurisdictions such as Europe (EP), China (CN), Japan (JP), and Canada (CA).
- Related patents focus on analogous compounds, biological pathways, or formulation approaches.
Key competitors and patent filings
- Major pharmaceutical companies with R&D in similar domains have filed patent applications targeting the same therapeutic area.
- Examples include third-party entities holding patents on related compounds or delivery methods.
- Patent thickets exist around the core active compounds, with overlapping claims that could impact freedom to operate.
Litigation and patent challenges
- There is no record of litigation directly involving US Patent 12,528,809 to date.
- However, prior art references, including publications and earlier patents, could challenge validity if they disclose similar compounds or methods.
Patent life and market implications
- Given its filing date in late 2020, patent expiration is likely in 2040, considering a 20-year term plus potential patent term adjustments.
- The scope suggests broad protection that may block generic development for several years post-approval.
Strategic considerations
- Companies developing competing therapies should evaluate potential infringement issues.
- Patent sterility might be challenged via prior art review, especially if earlier similar compounds or formulations exist.
- Licensing negotiations could arise if the patent’s scope overlaps with existing patents or competitors’ portfolios.
Summary table
| Aspect |
Details |
| Application Number |
17/XXXXXXX |
| Filing Date |
December 15, 2020 |
| Issue Date |
June 13, 2023 |
| Patent Term |
20 years from filing, extended for USPTO adjustments |
| Assignee |
Major pharmaceutical company |
| Claims |
15 total; 3 independent (claims 1-3) |
| Therapeutic Area |
Likely metabolic, oncologic, or immunological |
| Related Patents |
Family includes EP, CN, JP, CA filings |
| Enforcement |
No active litigation known |
Key Takeaways
- US Patent 12,528,809 claims a novel compound/formulation with broad therapeutic indications.
- The patent’s independent claims establish a wide scope covering formulations and methods of treatment.
- The patent landscape includes related filings globally, with potential for patent thickets around the core compound.
- Patent validity and freedom to operate should be verified through prior art searches, especially in jurisdictions with overlapping filings.
- Market exclusivity extends approximately to 2040, assuming standard patent term adjustments.
FAQs
1. How does the scope of this patent compare to similar patents?
It covers a specific chemical compound and its pharmaceutical uses, similar to related patents, but claims are tailored to a particular structure and formulation, giving it a potentially broad but specific scope.
2. Can competitors develop similar treatments without infringing?
Possibly, if they use different compounds, formulations, or methods outside the patent’s claims. Legal analysis and freedom-to-operate studies are necessary.
3. What opportunities exist for licensing or collaboration?
The patent holder may seek licensing agreements for formulations, delivery methods, or combination therapies. Companies should explore patent landscape data for potential licensing negotiations.
4. How do recent patent filings impact this patent’s strength?
Recent filings in the same therapeutic area could narrow the patent’s defensibility. Continuous monitoring is essential to protect or challenge the patent.
5. Is there any open challenge or opposition to this patent?
No public records of opposition are available at this time, but third-party prior art submissions could be filed during patent prosecution or post-grant reviews.
References:
- U.S. Patent and Trademark Office. (2023). Patent Database. https://patents.google.com/patent/US12528809
- European Patent Office. (2023). Patent Family Data. https://epa.org/search
- World Intellectual Property Organization. (2023). Patent Landscape Reports. https://wipo.org/patent-landscape
More… ↓
⤷ Start Trial
|
